๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Esophageal Cancer
Clinical trial register · China

Esophageal Cancer Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 22 Shanghai 20 Hangzhou 12 Zhengzhou 12 Tianjin 9
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences7 Tianjin Medical University Cancer Institute and Hospital6 Zhejiang University5 Sun Yat-sen University5 Fudan University5
Site location
Beijing22 Shanghai20 Hangzhou12 Zhengzhou12 Tianjin9
All 50 locations
Target enrolment
to

Esophageal Cancer trials in China

90 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function
NCT05048368Esophageal Cancer, Advanced Solid Tumor
Sunshine Lake Pharma Co., Ltd.
Phase 1
32
Chengdu
2026-10-30
Not yet open
A Non-inferiority Study of Indocyanine Green-guided Sentinel Lymph Node Mapping Versus Conventional Lymph Node Dissection in Esophageal Cancer
NCT07788001Esophageal Cancer, Sentinel Lymph Node, Lymphadenectomy, Indocyanine Green (ICG)
Fujian Medical University Union Hospital
Phase 3
200
Fuzhou
2026-10-01
Not yet open
Phase Ib Study of Oral R01 Monotherapy in Advanced Solid Tumors
NCT07806500Squamous Cell Lung Cancer, Gastric Cancer, Esophageal Cancer
Beijing Anjianxi Bio-Medical Technology Co., Ltd.
Phase 1
18
Beijing
2026-09
Not yet open
Study of Adebrelimab Combined With Thymalfasin and Chemotherapy for Neoadjuvant Treatment of Esophageal Cancer
NCT07780721Esophageal Cancer
DrugsThymalfasin·Adebrelimab
The Affiliated Hospital of Putian University
Phase 2
31
Putian
2026-08-30
Not yet open
High-Flow Nasal Cannula Oxygenation During Sedated Gastrointestinal Endoscopy in Patients With Chronic Obstructive Pulmonary Disease
NCT07791979Hypoxemia, Gastric Cancer (Diagnosis), Chronic Obstructive Pulmonary Disease (COPD), Esophageal Cancer
Zhejiang University
Not applicable
90
Hangzhou
2026-08-29
Not yet open
An Exploratory Clinical Study of Accurate Efficacy Assessment of Neoadjuvant Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma Based on 68Ga-FAPI ([68Ga] Fibroblast Activation Protein Inhibitor)/ยนโธF-FDG (2-Deoxy-2-[ยนโธF]Fluoro-D-glucose) Dual Imaging
NCT07770672Esophageal Cancer, ESCC
DrugsRetlirafusp alfa·Adebrelimab
Tan Lijie
Phase 2
92
Shanghai
2026-08-20
Recruiting
Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC
NCT07733830Esophageal Cancer
DrugsAdebrelimab·Nab-paclitaxel·Carboplatin
Tianjin Medical University Cancer Institute and Hospital
Phase 2
120
Beijing, Zhengzhou, Shenyang, Taiyuan, Chengdu, Tianjin
2026-07-31
Not yet open
The Value of Near-Infrared Fluorescence Imaging in the Protection of the Recurrent Laryngeal Nerve During Minimally Invasive Esophagectomy
NCT07406815Esophageal Cancer, Recurrent Laryngeal Nerve, ICG (Indocyanine Green), Lymph Node Dissection
Fujian Medical University Union Hospital
Phase 3
144
Fuzhou
2026-06-01
By invitation
Large-scale Models of Esophageal Cancer and Related Research
NCT07642401Esophageal Cancer
The First Affiliated Hospital of Henan University of Science and Technology
Observational
12,000
Anyang, Luoyang, Nanyang
2026-05-15
Recruiting
The Application of Symptoms Management Program Based on the Patient Reported Outcome After Esophagectomy
NCT07187154Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
300
Beijing
2026-05-02
Recruiting
Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer
NCT07367516Esophageal Cancer
DrugTQB6411
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
105
Hefei, Beijing, Fuzhou, Lanzhou, Shantou, Nanning, Guangxi, Zunyi
2026-02-12
Recruiting
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
NCT07431281Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer
DrugsSonesitatug Vedotin·Zolbetuximab·Rilvegostomig·Leucovorin
AstraZeneca
Phase 3
2,130
Beijing, Changde, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin
2026-02-03
Not yet open
Indocyanine Green-guided Omental Shield Anastomosis for Cervical Esophagogastric Anastomosis in Minimally Invasive McKeown Esophagectomy
NCT07376876Esophageal Squamous Cell Carcinoma (ESCC), Esophageal Cancer
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2
73
Chongqing
2026-01-01
Not yet open
The Value of Indocyanine Green-guided Near-infrared Fluorescence Technology in Tracing Sentinel Lymph Nodes During Esophagectomy
NCT07303231Esophageal Cancer, Sentinel Lymph Node, Lymphadenectomy, Indocyanine Green
Fujian Medical University Union Hospital
Phase 3
144
Fuzhou
2026-01-01
Recruiting
High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients
NCT07307560Hypoxia, Esophageal Cancer, Gastric Cancer (Diagnosis), Obstructive Sleep Apnea (OSA)
Zhejiang University
Not applicable
600
Hangzhou, Jiaxing, Quzhou
2025-12-21
By invitation
Based on ctDNA-MRD Guided Adjuvant Treatment Escalation After Definitive Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Study on Safety and Efficacy
NCT07371247Esophageal Cancer, MRD, ctDNA
The First Affiliated Hospital with Nanjing Medical University
Phase EARLY_PHASE1
65
Nanjing
2025-12-20
Recruiting
DCRT vs. Surgery in Resectable ESCC Patient Achiving cCR/PR After nCI
NCT07162506Esophageal Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
120
Tianjin
2025-11-03
Recruiting
Combination of COMBO Endoscopy Oropharyngeal Airway and HFNC Oxygenation in Sedated Gastrointestinal Endoscopy for Morbidly Obese Patients
NCT07175155Hypoxemia, Esophageal Cancer, Morbidly Obese Patients, Gastric Cancer
Zhejiang University
Not applicable
410
Beijing, Jinjiang, Hangzhou, Lishui, Taizhou
2025-10-24
Recruiting
Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC
NCT07177794Esophageal Cancer, Chemoradiotherapy
DrugsJS001·Xeloda·Toripalimab·Capecitabine
Sun Yat-sen University
Phase 3
242
Guangzhou
2025-09-10
Recruiting
Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC
NCT07038629Esophageal Cancer
DrugIparomlimab
Tianjin Medical University Cancer Institute and Hospital
Phase 2
52
Tianjin
2025-09-08
Recruiting
Clinical Application of PET Imaging Targeting CLDN18.2 in Malignant Tumors
NCT07301814Gastric Cancer, Pancreatic Cancer, Cholangiocarcinoma Cancer, Esophageal Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
56
Wuhan
2025-09-01
Not yet open
Endostatin Adenovirus With Checkpoint Inhibitor in Advanced Head and Neck or Esophageal Cancer
NCT07154108Esophageal Cancer, Head and Neck Cancer (H&Amp;Amp;Amp;N)
Sichuan University
Phase 1
40
Chengdu
2025-09-01
Recruiting
A Multi Tumor, Open Phase I Clinical Study on the Progression of First-line Anti-tumor Therapy Using Cardonizumab Combined With Pulsed Low-dose Rate External Irradiation (PLDR)
NCT06232083Lung Cancer, Esophageal Cancer, Cervical Cancer
Anhui Provincial Hospital
Phase 1
20
Hefei
2025-09-01
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
NCT07181473Lung Cancer (NSCLC), Prostate Cancer, Esophageal Cancer, Solid Tumor Malignancies
Phrontline Biopharma
Phase 1
200
Zhengzhou, Wuhan, Hangzhou, Shanghai
2025-08-25
Recruiting
Development and Validation of a Risk Prediction Model for Gastric Retention in Patients Undergoing Sedated Gastroscopy
NCT07104214Gastric Cancer Stage, Esophageal Cancer, Gastroparesis
Zhejiang University
Observational
5,000
Hangzhou, Jiaxing, Lishui
2025-08-03
Recruiting
Oncolytic Virus in Esophageal Squamous Cell Carcinoma
NCT07061704Esophageal Cancer
Sichuan University
Phase 1/2
40
Chengdu
2025-08-01
Recruiting
Integrating Multimodal AI to Predict Treatment Response and Refine Risk Stratification in Esophageal Cancer ๏ผˆRadiogenomics-Esophagus๏ผ‰
NCT07354295Esophageal Cancer
Shu Peng
Observational
1,500
Wuhan
2025-07-26
Recruiting
Incidence of 106TBL Lymph Node Metastasis
NCT07165210Esophageal Cancer
Fudan University
Observational
1,852
Shanghai
2025-07-21
Recruiting
Incidence of 107 Lymph Node Metastasis
NCT07165184Esophageal Cancer
Fudan University
Observational
1,100
Shanghai
2025-07-21
Recruiting
Investigating Multigene Methylation Dynamics in Treatment Response Surveillance for Esophageal Carcinoma
NCT06979869Esophageal Cancer
Xijing Hospital
Observational
300
Wuwei, Shantou, Zhaoqing, Zhengzhou, Xi'an, Yanโ€™an, Taiyuan, Chengdu
2025-05-26
Recruiting
A Study of Bemosubaiabimab Combined With Anlotinib and Radiotherapy and Chemotherapy for the Treatment of Oligometastatic Esophageal Cancer
NCT07455019Esophageal Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2
28
Nanjing
2025-05-01
Recruiting
Comparison of Drainage Methods in Minimally Invasive Esophagectomy (DEMURE๏ผ‰
NCT07004634Esophageal Cancer, Drainage/Methods, Postoperative Pain
Ruijin Hospital
Not applicable
75
Shanghai
2025-04-30
Recruiting
A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal Cancer
NCT06869226Esophageal Cancer
DrugsCamrelizumab·Nab-paclitaxel·Cisplatin
Peking University Cancer Hospital & Institute
Phase 2
283
Beijing
2025-04-30
Recruiting
COMBO Endoscopy Oropharyngeal Airway Reduces Hypoxia During Sedated Gastrointestinal Endoscopy in Obese Patients: A Multicenter, Randomized, Controlled Clinical Trial
NCT06796764Hypoxia, Esophageal Cancer, Gastric Cancer
Zhejiang University
Not applicable
580
Hangzhou
2025-04-11
Not yet open
Prognostic Analysis of Esophageal Cancer with Complete Pathological Response After Neoadjuvant Therapy
NCT06889402Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
600
Beijing
2025-04-01
Recruiting
Patient Derived Organoids (PDOs) to Observe the Clinical Consistency of Personalized Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma
NCT07054086Esophageal Cancer
Shanghai Zhongshan Hospital
Observational
30
Shanghai
2025-03-01
Recruiting
A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy
NCT06769113Esophageal Cancer
DrugHLX43
Shanghai Henlius Biotech
Phase 2
102
Jinan
2025-01-26
Recruiting
Precision Palliative Care for Patients With Advanced Esophageal Cancer
NCT06787313Esophageal Cancer
Fudan University
Observational
624
Shanghai
2024-12-31
Not yet open
Safety and Efficacy Study of Pulsed Electric Field (PEF) Therapy in Patients With Advanced or Unresectable Esophageal Squamous Cell Carcinoma
NCT06756841Esophageal Cancer
Energenx Medical LTD.
Not applicable
10
Shanghai
2024-12-25
Recruiting
A Multicenter Prospective Study Evaluating Concurrent Chemoradiotherapy Following Induction Immunochemotherapy for Esophageal Cancer Based on Dynamic ctDNA Monitoring
NCT06792786Esophageal Cancer, ctDNA
The Central Hospital of Lishui City
Not applicable
30
Jinhua, Lishui
2024-12-10
Recruiting
Effect of Premedication With Pronase on Mucosal Cleanliness During EGD
NCT06713421Esophageal Cancer, Gastric Cancer
DrugsDimethicone·Pronase
Changhai Hospital
Not applicable
3,000
Shanghai
2024-12-01
Recruiting
DCE-MRI Based on 4D Free Breathing for Predicting Preoperative Neoadjuvant Chemoradiotherapy for Esophageal Cancer
NCT06755866Esophageal Cancer
Yunnan Cancer Hospital
Not applicable
135
Kunming
2024-11-26
Recruiting
Comparison of Endoscopy and Esophagram for the Routine Evaluation of Anastomosis After McKeown Esophagectomy
NCT07043491Esophageal Cancer, Surgery-Complications
Sun Yat-sen University
Observational
2
Guangzhou
2024-11-04
Active, closed
Cola Ingestion for Esophageal Bolus Impaction
NCT06652620Esophageal Cancer
Fudan University
Not applicable
50
Xiamen, Yangzhou, Jingdezhen, Shanghai
2024-11-01
Recruiting
Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles Study
NCT06663059Esophageal Cancer
DrugAdebrelimab
Tang-Du Hospital
Phase 2
80
Xi'an
2024-10-01
Recruiting
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
NCT06469944Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
DrugsPatritumab deruxtecan·Xeloda·Sacituzumab tirumotecan·Leucovorin
Merck Sharp & Dohme LLC
Phase 1/2
160
Beijing, Fuzhou, Xiamen, Zhengzhou, Nanchang, Shanghai, รœrรผmqi, Hangzhou
2024-09-20
By invitation
Hematoporphyrin Photodynamic Therapy for Esophageal Cancer
NCT06437288Esophageal Cancer, Photodynamic Therapy
Sun Yat-sen University
Phase 4
198
Guangzhou
2024-09-18
Recruiting
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer
NCT06532799Stomach Cancer, Stomach Cancer Recurrent, Stomach Cancer, Adenocarcinoma, Esophageal Cancer
DrugsCyclophosphamid·Tumor Infiltrating Lymphocytes·Aldesleukin·Fludarabine
Essen Biotech
Phase 1/2
75
Beijing
2024-09-10
Recruiting
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
NCT06445972Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
DrugsPatritumab deruxtecan·Ramucirumab·Sacituzumab tirumotecan·Paclitaxel
Merck Sharp & Dohme LLC
Phase 1/2
210
Beijing, Fuzhou, Xiamen, Zhengzhou, Nanchang, Shanghai, รœrรผmqi, Hangzhou
2024-08-07
Recruiting
A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors
NCT06500052Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Colorectal Cancer
DrugBL-M17D1
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
20
Guangzhou
2024-07-24
Recruiting
Effectiveness of Risk-based Sequential Screening for Esophageal and Gastric Cancer
NCT06306755Esophageal Cancer, Gastric Cancer, Precision Screening, Sequential Screening
Peking University Cancer Hospital & Institute
Not applicable
21,000
Beijing
2024-06-25
Recruiting
Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With ESCC.
NCT06452602Esophageal Cancer
DrugConcurrent chemoradiotherapy
Tianjin Medical University Cancer Institute and Hospital
Phase 2
60
Tianjin
2024-06-19
Not yet open
Neoadjuvant Immunochemotherapy for Adenocarcinoma of the Esophagogastric Junction
NCT06469060Esophageal Cancer
Shanghai Chest Hospital
Phase 2
34
Shanghai
2024-06-19
Recruiting
Neoadjuvant PD-1 Blockade for Elderly Esophageal Squamous Cell Carcinoma (BLESS)
NCT06385730Esophageal Cancer
DrugNeoadjuvant anti-PD-1
Shanghai Chest Hospital
Phase 2
60
Shanghai
2024-06-17
Recruiting
Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma
NCT06413342Esophageal Cancer, Chemoradiotherapy, Sintilimab, Immunotherapy
DrugSintilimab
Zhejiang Cancer Hospital
Phase 2
191
Hangzhou
2024-06-01
Active, closed
Clinical Study on the Impact of Eradication of Oral Porphyromonas Gingivalis on the Prognosis of Early Esophageal Cancer After ESD Surgery
NCT06722300Esophageal Cancer
The First Affiliated Hospital of Henan University of Science and Technology
Not applicable
856
Luoyang
2024-05-01
Recruiting
An Organ Preservation Strategies After Chemoradiotherapy Combined With Immunotherapy for Esophageal Cancer (PALACE3).
NCT06339060Esophageal Cancer
Ruijin Hospital
Phase 3
356
Shanghai
2024-05-01
Recruiting
Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer
NCT06421376Esophageal Cancer, Immunotherapy, Induction Therapy, Chemoradiotherapy
DrugCardonilizumab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
60
Anyang, Xinxiang, Beijing
2024-05-01
By invitation
Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors
NCT06690216Glioblastoma (GBM), Head and Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Esophageal Cancer
Man Hu
Phase 1/2
100
Jinan
2024-03-30
Recruiting
Pembrolizumab Combined With Preoperative Chemotherapy (Albumin Paclitaxel+Carboplatin) Neoadjuvant Therapy for Resectable Locally Advanced (Stage II/III) Esophageal Squamous Cell Carcinoma
NCT06304350Esophageal Cancer
Tongji University
Phase 2
25
Shanghai
2024-02-17
Recruiting
The Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway in Gastrointestinal Endoscopy Procedure
NCT06081647Hypoxia, Gastric Polyp, Colon Cancer, Esophageal Cancer
RenJi Hospital
Not applicable
1,200
Nanjing, Nanchang, Jinan, Shanghai, Xiโ€™an, Tianjin, Hangzhou
2023-12-27
Recruiting
A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors
NCT06008054Esophageal Cancer, Gastric Cancer, Colorectal Cancer
DrugsSI-B003·Iza-bren
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
376
Beijing
2023-11-16
Recruiting
Tislelizumab Plus Concurrent Chemoradiation in Older With ESCC
NCT06061146Esophageal Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2
136
Tianjin
2023-10-05
Recruiting
a Single-arm, Single-center, Open Clinical Study
NCT06431100Gastric Cancer, Esophageal Cancer, Cervical Cancer, Non-Small Cell Lung Cancer NSCLC
Beijing Geekgene Technology Co., LTD
Observational
10
Zhengzhou
2023-07-19
Recruiting
Influence Mechanism of Tumor Microenvironment Changes on Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma
NCT05894369Esophageal Cancer
Renmin Hospital of Wuhan University
Observational
10
Wuhan
2023-05-04
Recruiting
The Effect of Chronic Stress on Efficacy of ICIs in Esophageal Cancer Patients (STRESS-ESCA Study)
NCT05967910Esophageal Cancer, Immunotherapy
Second Xiangya Hospital of Central South University
Observational
200
Changsha
2023-05-01
Recruiting
Efficacy and Safety of Penpulimab Combined With Anlotinib and Chemotherapy
NCT06586242Esophageal Cancer
DrugsLobaplatin·Penpulimab·Albumin paclitaxel·Anlotinib
Xijing Hospital
Phase 2
194
Xi'an
2023-04-03
Recruiting
Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma
NCT06718205Esophageal Cancer
DrugsPaclitaxel-albumin·Nimotuzumab·Sintilimab·Cisplatin
The First Affiliated Hospital of Zhengzhou University
Phase 2
112
Zhengzhou
2023-03-08
Recruiting
Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma
NCT06410651Esophageal Cancer, Nimotuzumab, Chemoradiotherapy, Chemotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
53
Beijing
2023-03-01
Recruiting
Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients
NCT06429839Esophageal Cancer, Nimotuzumab, Chemoradiotherapy, Chemotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
55
Beijing
2023-03-01
Recruiting
Investigating the Biomarkers in Tumor and Peripheral Blood to Evaluate the Efficacy of Cancer Immunotherapy in Chest Cancer Patients
NCT06790797Lung Cancer, Esophageal Cancer
Zhao Jun
Observational
50
Suzhou
2023-02-12
Recruiting
Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma
NCT05978193Esophageal Squamous Cell Carcinoma, Esophageal Cancer, Metastatic Esophageal Squamous Cell Carcinoma
Shanghai Chest Hospital
Phase 2
100
Shanghai
2023-01-01
Recruiting
PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)
NCT05357846Squamous Cell Esophageal Carcinoma, Esophageal Cancer, Oesophageal Cancer
DrugsTaxol·Sintilimab·Paclitaxel·Cisplatin
Sun Yat-sen University
Phase 3
422
Guangzhou
2022-11-01
Recruiting
Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)
NCT05443841Esophageal Cancer
Fudan University
Observational
385
Hefei, Shijiazhuang, Zhengzhou, Nantong, Taishing, Taizhou, Xi'an, Tianjin
2022-07-18
Recruiting
The Level of Patient Participation in Lung and Esophageal Cancer Patients Treated With Definitive Radiochemotherapy.
NCT06019455Lung Cancer, Esophageal Cancer
Sun Yat-sen University
Observational
500
Guangzhou
2022-06-01
Recruiting
A Study of Perioperative Camrelizumab Combined With Chemotherapy in Patients With Resectable ESCC
NCT05182944Esophageal Cancer
The First Affiliated Hospital of Zhengzhou University
Phase 2
130
Zhengzhou
2022-01-15
Active, closed
A Study on the Impact of Intelligent Nutrition Management on Clinical Outcomes in Chemotherapy Patients With Gastrointestinal Malignancies
NCT06997302Gastric (Stomach) Cancer, Esophageal Cancer
Tianjin Medical University Cancer Institute and Hospital
Not applicable
150
Tianjin
2022-01-01
Not yet open
Clinical Study on the Efficacy of Single-port Inflatable Mediastinoscopy Combined With Laparoscopic-assisted Small Incision Surgery and Thoracoscopy Combined With Laparoscopic Surgery for Radical Esophagectomy
NCT05105945Esophageal Cancer
Fifth Affiliated Hospital, Sun Yat-Sen University
Not applicable
1,164
Zhuhai
2021-11-11
Active, closed
Sintilimab Combined With Chemotherapy Induction Therapy Followed by CCRT vs. CCRT for Esophageal Cancer: A Randomized Controlled Phase โ…ข Clinical Study
NCT07306663Esophageal Cancer
DrugSintilimab
Jiangsu Cancer Institute & Hospital
Phase 3
242
Nanjing
2021-06-01
Recruiting
Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer
NCT04415853Esophageal Cancer
Sunshine Lake Pharma Co., Ltd.
Phase 3
416
Beijing
2021-01-21
Not yet open
A Real-world Study Evaluating the Usage of Camrelizumab in Chinese Patients With Advanced Esophageal Cancer
NCT04616040Esophageal Cancer
DrugCamrelizumab
Peking University
Observational
1,030
Beijing
2020-12-01
Recruiting
Total Intravenous Anesthesia and Recurrence Free Survival
NCT04513808Esophageal Cancer
DrugsSevoflurane·Propofol
The Cleveland Clinic
Phase 3
1,614
Shanghai
2020-08-15
Recruiting
Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer
NCT04688801Esophageal Cancer, Gastroesophageal Cancer, Immunotherapy, Adjuvant
The Second Hospital of Shandong University
Not applicable
200
Jinan
2020-07-01
Recruiting
Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma
NCT04280822Esophageal Cancer, Surgery, Neoadjuvant Treatment, Survival
Henan Cancer Hospital
Phase 3
400
Zhengzhou
2020-04-21
Recruiting
A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
NCT03736863Esophageal Cancer
DrugsSHR-A2009·Apatinib
The First Affiliated Hospital of Zhengzhou University
Phase 2
147
Zhengzhou
2019-12-05
Recruiting
Chemoradiotherapy in Unresectable Esophageal Cancer
NCT04278287Esophageal Cancer, Chemoradiotherapy, Albumin-bound Paxlitaxel, Unresectable Malignant Neoplasm
DrugsAlbumin-Bound Paclitaxel·Nab-paclitaxel·Cisplatin
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1/2
105
Anyang, Changsha, Nanjing, Beijing
2019-10-01
Recruiting
Comparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell Carcinoma
NCT04135664Esophageal Cancer
Shanghai Chest Hospital
Phase 3
176
Nanchang, Shanghai, Tianjin
2019-09-01
Recruiting
APG-2449 in Patients With Advanced Solid Tumors
NCT03917043Advanced Solid Cancer, Non Small Cell Lung Cancer, Esophageal Cancer, Ovarian Cancer
DrugAPG -2449
Ascentage Pharma Group Inc.
Phase 1
165
Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Hangzhou
2019-05-27
Recruiting
Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients
NCT03731442Esophageal Cancer
DrugsPEG-rhG-CSF·Paclitaxel
Chinese Academy of Medical Sciences
Phase 3
300
Beijing
2018-11-01
Recruiting
Neoadjuvant Treatment Modalities in Esophageal Cancer
NCT04821843Esophageal Cancer, Chemotherapy Effect, Chemoradiation, Surgery
DrugNimotuzumab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3
2,000
Beijing
2002-01-01
Rows per page Showing 1–90 of 90
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 29 September 2026. https://priyalifescience.com/clinical-trials-china/condition/esophageal-cancer

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 90 of those studies listing the condition Esophageal Cancer.

How many Esophageal Cancer trials are recruiting in China?

67 of the 90 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 15 have not yet opened recruitment, 4 are active but closed to new participants, and 4 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Esophageal Cancer), 90 studies
PhaseStudiesRecruitingShare
Phase 2252127.8%
Observational181520%
Not applicable171118.9%
Phase 3141015.6%
Phase 1747.8%
Phase 1/2767.8%
Phase 4101.1%
Phase EARLY_PHASE1101.1%

Most active sponsors

Lead sponsors with the most studies (Esophageal Cancer)
Lead sponsorStudiesRecruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences76
Tianjin Medical University Cancer Institute and Hospital65
Fudan University54
Sun Yat-sen University54
Zhejiang University54
Shanghai Chest Hospital43
Fujian Medical University Union Hospital30
The First Affiliated Hospital of Zhengzhou University33
Merck Sharp & Dohme LLC22
Peking University Cancer Hospital & Institute22
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.